[go: up one dir, main page]

EA036102B9 - Терапевтические средства с углевод-опосредованной адресной доставкой - Google Patents

Терапевтические средства с углевод-опосредованной адресной доставкой

Info

Publication number
EA036102B9
EA036102B9 EA201890778A EA201890778A EA036102B9 EA 036102 B9 EA036102 B9 EA 036102B9 EA 201890778 A EA201890778 A EA 201890778A EA 201890778 A EA201890778 A EA 201890778A EA 036102 B9 EA036102 B9 EA 036102B9
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
immune response
unwanted immune
compounds
disclosed compounds
Prior art date
Application number
EA201890778A
Other languages
English (en)
Other versions
EA201890778A1 (ru
EA036102B1 (ru
Inventor
Джеффри А. Хаббелл
Дэвид Скотт Уилсон
Original Assignee
Эколь Политекник Федераль Де Лозан
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/859,292 external-priority patent/US10946079B2/en
Priority claimed from US15/185,564 external-priority patent/US10046056B2/en
Application filed by Эколь Политекник Федераль Де Лозан filed Critical Эколь Политекник Федераль Де Лозан
Publication of EA201890778A1 publication Critical patent/EA201890778A1/ru
Publication of EA036102B1 publication Critical patent/EA036102B1/ru
Publication of EA036102B9 publication Critical patent/EA036102B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C08F2/38—Polymerisation using regulators, e.g. chain terminating agents, e.g. telomerisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Изобретение относится к соединениям для индукции толератности к антигену, который индуцирует нежелательный иммунный ответ, а также к композиции, содержащей раскрытые соединения, и способу лечения нежелательного иммунного ответа на антиген, предусматривающий введение эффективного количества раскрытых соединений млекопитающему, нуждающемуся в лечении.
EA201890778A 2015-09-19 2016-09-16 Терапевтические средства с углевод-опосредованной адресной доставкой EA036102B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/859,292 US10946079B2 (en) 2014-02-21 2015-09-19 Glycotargeting therapeutics
US15/185,564 US10046056B2 (en) 2014-02-21 2016-06-17 Glycotargeting therapeutics
PCT/IB2016/001411 WO2017046652A1 (en) 2015-09-19 2016-09-16 Glycotargeting therapeutics

Publications (3)

Publication Number Publication Date
EA201890778A1 EA201890778A1 (ru) 2018-08-31
EA036102B1 EA036102B1 (ru) 2020-09-29
EA036102B9 true EA036102B9 (ru) 2020-12-30

Family

ID=57121450

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890778A EA036102B9 (ru) 2015-09-19 2016-09-16 Терапевтические средства с углевод-опосредованной адресной доставкой

Country Status (12)

Country Link
EP (2) EP3349784A1 (ru)
JP (3) JP7082045B2 (ru)
KR (1) KR20180080195A (ru)
CN (3) CN118436774A (ru)
AU (2) AU2016325073B2 (ru)
CA (1) CA2998066A1 (ru)
EA (1) EA036102B9 (ru)
HK (1) HK1257845A1 (ru)
IL (3) IL306015B2 (ru)
MX (1) MX2018003411A (ru)
NZ (2) NZ780072A (ru)
WO (1) WO2017046652A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3107563B1 (en) 2014-02-21 2021-04-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
IL306015B2 (en) * 2015-09-19 2025-05-01 Ecole Polytechnique Fed Lausanne Epfl Glyco-directed therapy
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019069993A1 (en) 2017-10-03 2019-04-11 Chugai Seiyaku Kabushiki Kaisha ANTI-HLA-DQ2.5 ANTIBODIES
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
CN111214461B (zh) 2020-03-24 2021-04-16 河南大学 糖靶向修饰siRNA纳米粒子的制备及应用
CN116819072B (zh) * 2023-08-28 2023-11-17 迪亚莱博（张家港）生物科技有限公司 一种用于抗aqp4自身抗体检测的抗原蛋白组合物及化学发光检测试剂盒
WO2025210538A1 (en) * 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011086143A2 (en) * 2010-01-14 2011-07-21 Glaxo Group Limited Liver targeting molecules
WO2012083185A2 (en) * 2010-12-17 2012-06-21 Arrowhead Research Corporations Peptide-based in vivo sirna delivery system
WO2013121296A1 (en) * 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
WO2015140648A2 (en) * 2014-02-21 2015-09-24 Ecole Polytecnique Federale De Lausanne (Epfl) Epfl-Tto Glycotargeting therapeutics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571431A1 (en) 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
IL306015B2 (en) 2015-09-19 2025-05-01 Ecole Polytechnique Fed Lausanne Epfl Glyco-directed therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011086143A2 (en) * 2010-01-14 2011-07-21 Glaxo Group Limited Liver targeting molecules
WO2012083185A2 (en) * 2010-12-17 2012-06-21 Arrowhead Research Corporations Peptide-based in vivo sirna delivery system
WO2013121296A1 (en) * 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
WO2015140648A2 (en) * 2014-02-21 2015-09-24 Ecole Polytecnique Federale De Lausanne (Epfl) Epfl-Tto Glycotargeting therapeutics

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLA TRAHTENHERTS, ITAI BENHAR: "An Internalizing Antibody Specific for the Human Asialoglycoprotein Receptor", HYBRIDOMA, MARY ANN LIEBERT, vol. 28, no. 4, 1 August 2009 (2009-08-01), pages 225 - 233, XP055084704, ISSN: 15540014, DOI: 10.1089/hyb.2009.0019 *
BARNEY YOO, SARAH M. CHEAL, GERALDA TORCHON, ANNA DILHAS, GUANGBIN YANG, JUN PU, BLESIDA PUNZALAN, STEVEN M. LARSON, OUATHEK OUERF: "N -Acetylgalactosamino Dendrons as Clearing Agents to Enhance Liver Targeting of Model Antibody-Fusion Protein", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 24, no. 12, 18 December 2013 (2013-12-18), pages 2088 - 2103, XP055224623, ISSN: 1043-1802, DOI: 10.1021/bc400333m *
COULSTOCK E, SOSABOWSKI J, OVEČKA M, PRINCE R, GOODALL L, MUDD C, SEPP A, DAVIES M, FOSTER J, BURNET J, DUNLEVY G, WALKER A.: "Liver-targeting of interferon-alpha with tissue-specific domain antibodies.", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 8, no. 2, 1 January 2013 (2013-01-01), US, pages e57263 - e57263-11, XP002697904, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0057263 *
MEAGER A ET AL: "Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 132, no. 1, 1 April 2003 (2003-04-01), GB, pages 128 - 136, XP002470334, ISSN: 0009-9104, DOI: 10.1046/j.1365-2249.2003.02113.x *
S. KONTOS, I. C. KOURTIS, K. Y. DANE, J. A. HUBBELL: "PNAS Plus: Engineering antigens for in situ erythrocyte binding induces T-cell deletion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 1, 2 January 2013 (2013-01-02), pages E60 - E68, XP055068885, ISSN: 00278424, DOI: 10.1073/pnas.1216353110 *
SREEMAN K. MAMIDYALA: "Glycomimetic Ligands for the Human Asialoglycoprotein Receptor", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, no. 4, 24 January 2012 (2012-01-24), pages 1978 - 1981, XP055048572, DOI: 10.1021/ja2104679 *
XIAORONG ZHAO, ZHEN YU, WENTAO DAI, ZHENJIANG YAO, WEI ZHOU, WEIPING ZHOU, JUNLI ZHOU, YONGGANG YANG, YINCHANG ZHU, SIDONG CHEN, L: "Construction and characterization of an anti-asialoglycoprotein receptor single-chain variable-fragment-targeted melittin", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 58, no. 6, 1 November 2011 (2011-11-01), pages 405 - 411, XP055084712, ISSN: 08854513, DOI: 10.1002/bab.57 *

Also Published As

Publication number Publication date
IL306015B2 (en) 2025-05-01
IL257958B2 (en) 2024-02-01
JP2018532722A (ja) 2018-11-08
CN118436774A (zh) 2024-08-06
CA2998066A1 (en) 2017-03-23
IL257958B1 (en) 2023-10-01
AU2016325073A1 (en) 2018-04-05
IL257958A (en) 2018-06-28
EA201890778A1 (ru) 2018-08-31
JP2024063005A (ja) 2024-05-10
JP7434248B2 (ja) 2024-02-20
JP7082045B2 (ja) 2022-06-07
EP3349784A1 (en) 2018-07-25
AU2016325073B2 (en) 2023-03-16
EA036102B1 (ru) 2020-09-29
JP2022028673A (ja) 2022-02-16
EP4385520A2 (en) 2024-06-19
KR20180080195A (ko) 2018-07-11
CN108430497B (zh) 2024-05-07
CN118576700A (zh) 2024-09-03
HK1257845A1 (zh) 2019-11-01
BR112018005409A2 (pt) 2018-10-09
EP4385520A3 (en) 2024-09-11
WO2017046652A1 (en) 2017-03-23
AU2023203475A1 (en) 2023-06-29
IL306015B1 (en) 2025-01-01
IL317262A (en) 2025-01-01
NZ740689A (en) 2024-11-29
NZ780072A (en) 2024-11-29
NZ780070A (en) 2024-11-29
IL306015A (en) 2023-11-01
CN108430497A (zh) 2018-08-21
MX2018003411A (es) 2018-09-06
AU2023203475B2 (en) 2026-02-05

Similar Documents

Publication Publication Date Title
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201790413A1 (ru) Антитела против tigit
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201991071A1 (ru) Композиции и способы для лечения ezh2-опосредованного рака
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201590388A1 (ru) Способы лечения таупатии
EA201592203A1 (ru) Способы лечения таупатии
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201690898A1 (ru) Способы лечения таупатии
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent